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Environmentl and industriallead exposurs coninue t pose majorpublic healthproblems inchil-
dren and inadults.Acuteexposure tohigh concentration oflead can result inprouiml tubulardam-
age with dhracteristc and manisted by gbcosuria and aminoaciduria. Chronic
occupational exposure to lead, orconsumption ofillicit alcohol adulted withlead, has also been
linked toahi incidee ofrenaldysfuntion,whichischaracteized byglomerularandtbulointer-
stitialdcag resulting inchronic real filure, y n, hype and gout. Ahigh inci-
dence ofnephrpaywas reportd duringtheearypart ofthis centuryfiomQ nnd, A lia,
inpersonswith ahistoryofchildhoo leadpoisoning. No such sequelahas been found in studies of
thwe cohorts oflead-poisoned dcildren fiom the UnitedStates. Studies inind"iduals with low-level
leadexpoe have shown a correlation between bloodleadleves and serum creae or nine
clearance. Chroniclow-levelexposuretoleadisalso iatedwithincasedurnary xcretionoflow
molecular weight proteins and lysosomal enzymes. The relationship between renal dysfimction
detected by thse sensitive test and the E dvo e ofcict renal disease roemfains uncer-
tain. Ep ic studies haveshown an iion between bloodleadlevls andbloodpressure,
andhy tionisacardinalfeatureoflead ephrphy. Evidenceforinceasedbodyleadburden is
aprereqiste for the diagosis of eadnphropathy. Bloodlead levels are a pr indicator ofbody
lead burden and dlect recentcqepos. The EDTAleadmobilizationtest has been usedextensively
in the past to a bodylead burden. It is now rplacd byth less invasiv in vim X-ry fluores-
cence for d natin ofbone leadcontet Ay wends Naceqylf-Dlucosaminia , gout, heavy
metals,h ion, kidneyne opahy.
EnvinmHealhPepe,ct105:928-939(1997). hp//ehikniehs.n&ov
Lead is one of the most useful elements in
industry but serves no useful function in the
human body (1). Over the past 20 years, it
has become increasingly evident that low-level
lead exposure resulting in blood lead levels
between 10 and 15 pg/dl (0.48-0.72 pmol/l)
can lead to deleterious effects, particularly in
infants and young children (4. The effects of
chronic lead exposure include cognitive and
behavioral deficits (3,4), high blood pressure,
and impaired renal function. Since the late
1970s, there has been a substantial reduction
or elimination of environmental sources of
lead, including house paint, gasoline, water
distribution systems, and lead-soldered food
and soft drink cans (4). Pirkle et al. (5) used
the data from the National Health and
Nutrition Examination Surveys II and III and
found that, between 1976 and 1991, the
mean blood lead levels for the U.S. popula-
tion declined from 12.8 to 2.8 pg/dl
(0.61-0.13 pmol/l). As aresult, the acceptable
blood lead levels, also referred to as threshold
for action, have been reduced over the years
from <25 pg/dl (1.21 pmol/l) in 1985 to
<10 pg/dl (0.48 pmol/l) in 1991, but even
thecurrendyacceptedbloodleadlevel of<10
pg/dl (0.48 pmol/l) maybeexcessive (6).
The purpose ofthis review is to summa-
rize the current knowledge of the renal
effects of chronic lead exposure in humans.
Following a review of nephropathy due to
occupational lead exposure, I shall discuss
the evidence for lead nephropathy following
environmental lead exposure in childhood.
Other commonly observed symptoms of
chronic lead toxicity, indudinghypertension,
hyperuricemia, and gout will also be dis-
cussed. I shall conclude with a discussion of
the currently available laboratory tests for the
determination ofbody lead burden as well as
forevaluation ofrenal tubulareffects oflead.
Historical Aspects
Plumbism, or lead poisoning, has been rec-
ognized for many centuries and is one ofthe
oldest ailments afflicting humans. Nikander
(200 B.C.) was first to describe the symptoms
oflead poisoning, which included colic and
pallor (7). The English aristocracyofthe 17th
and 18th centuries suffered from widespread
lead poisoning from consumption of
Portuguese wine, transported with sub-
merged lead bars to enhance flavor and to
prevent spoilage (8). Lancereaux (1882) pro-
vided the first description of kidney disease
and interstitial nephritis by postmortem
examination ofa lead poisoned artist. Olivier
(9) also reported on kidney disease in lead
poisoning, but failed to differentiate intersti-
tial from glomerular disease (7). It was not
until the late 1920s when an epidemic of
chronic nephritis in Queensland, Australia,
was linked to childhood lead poisoning that
the full spectrum oflead-induced nephropa-
thy became apparent (10-12). This was fol-
lowed by reports of renal disease from the
Southeastern United States in individuals
consuming lead-contaminated illegally dis-
tilled (moonshine) whiskey (13) and in
industrial leadworkers (14).
Environmental Lead Exposure
Although many industrial sources of lead
have been eliminated, excessive environmen-
tal lead exposure continues to be a public
health problem. Seventy to 99% ofall hous-
es built prior to 1959 have painted-surfaces
containing significant amounts of lead
(15,16). Older housing is also more likely to
contain lead plumbing (17). In the past,
lead-based paint was a major source oflead
poisoning in children; however, direct inges-
tion oflead paint is now a much less com-
mon occurrence. Ingestion oflead-contami-
nated dust and water by children has been
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identified as a major contributor to lead
poisoning (15). In a recent survey of the
District of Columbia, high concentrations
of lead were found in soil samples from
inner-city areas, and lead-based paint was
found to be the main source oflead in soil
dust (18). That lead-contaminated dust is a
major determinant oflead concentrations in
blood has been confirmed by studies show-
ing a direct relationship between blood lead
levels and lead concentrations in the ground
(19). Campbell et al. (20) found a highly
significant correlation between lead concen-
trations in drinking water and blood lead
concentrations in 293 people living in
Scotland where the water lead levels were
>100 pg/l (4.83 pmol/l). An important-cur-
rent public health concern is continuing
high blood lead levels in children and the
means to reduce them (15). Children are
more susceptible to the effects of environ-
mental lead than adults because ofincreased
gastrointestinal absorption of lead in chil-
dren (21). Adults at highest risk are those
exposed to lead fumes or dust in industry
(22,23).
Lead Nephropathy
An association between lead poisoning and
renal disease in humans has been recognized
for over a century (8,12,24). The major renal
effect ofacute lead poisoning is disruption of
proximal tubular architecture, with laborato-
ryevidence ofdisturbances in proximal tubu-
lar function (25-28) (Fig. 1). Histologic
changes include eosinophilic intranuclear
indusions in proximal tubular cells consisting
oflead-protein complexes, and mitochondri-
al swelling (29-33). Renal manifestations of
acute lead poisoning have beenwell described
both in animal models and in humans; these
include glycosuria, aminoaciduria (34,35),
and phosphaturia, collectively representing
the Fanconi syndrome (36-38). These func-
tional changes are thought to be related to an
effect oflead on mitochondrial respiration
and phosphorylation (26). Recent studies
have shown that lead can directly inhibit the
function of ?BAT, a protein involved in the
high affinity transport ofneutral and dibasic
amino acids across renal and intestinal brush
borders (39). Because lead is also capable of
reducing 1,25-dihydroxyvitamin D synthesis
(40), prolonged hyperphosphaturia and
hypophosphatemia caused by lead poisoning
in children could result in bone demineraliza-
tion and rickets (36). The renal manifesta-
tions of acute lead poisoning are usually
reversible after chelation therapy and cessa-
tionofleadexposure (26,3.
Inexperimental animals, exposure tohigh
concentrations oflead results in increased
glomerular filtration (hyperfiltration) after 3
months ofexposure. This is followed by a
Figure 1. Consequences of excessive lead exposure. Abbreviations: MW, molecularweight; CRF, chronic
renal failure; NAG, N-acetyl-o-D-glucosaminidase. Acute lead poisoning results in proximal tubular dys-
function; these changes usually disappear with chelation therapy or removal from lead sources. Chronic
lead poisoning can affect glomerular function when blood lead levels exceed 60 pg/dl. After an initial peri-
od of hyperfiltration, the glomerular filtration is reduced and nephrosclerosis and chronic renal failure
ensue. Prolonged lead exposure also interferes with distal tubular secretion of urate, leading to hyper-
uricemia and gout. Finally, chronic lead exposure may cause hypertension, resulting from vasoconstric-
tion due tothe action of lead on the renin-angiotensin system (RAS) and on calcium signaling.
progressive decline in the glomerular filtra-
tion rate (GFR) and irreversible renal failure
by 12 months (41-43). A blood lead level of
60 jig/dl (2.89 pmol/l) appears to be the
threshold for proximal tubular injury in both
animal andhumanstudies.
In humans, the symptoms resulting
from chronic lead poisoning are subtle, and
often the patients remain asymptomatic
until significant reductions of renal func-
tion have occurred. As in experimental ani-
mals, chronic exposure to high levels oflead
results in irreversible changes in the kidney,
including interstitial fibrosis, tubular atro-
phy, glomerular sclerosis, and ultimately
renal failure, which necessitates replacement
therapy (26,28) (Fig. 1). These changes are
nonspecific and common to many other
types of renal injury; therefore, increased
lead burden must be ascertained and other
causes ofrenal failure ruled out before mak-
ing a diagnosis of lead nephropathy.
Chronic high-dose lead exposure has also
been implicated in the development ofgout
and hypertension (13,44).
Whether chronic lead nephropathy
exists as a dinical entity has been questioned
(45). Many studies ofoccupational leadpoi-
soning have not taken into account the
coexposure to other toxins such as cadmi-
um. Additionally, the relationship between
early markers of renal tubular dysfunction,
such as the urinary excretion oflowmolecu-
lar weight proteins or N-acetyl P-D-glu-
cosaminidase (NAG) to subsequentdevelop-
ment of renal failure, remains to be deter-
mined (46).
Chronic exposure to high concentrations
oflead results in ahigh incidence ofchronic
nephropathy (10,47-49). In general, indi-
viduals with blood lead levels exceeding 60
pg/dl (2.89 pmol/l) are at a definite risk of
developing renal failure (45,50). More
recently, it has become evident that blood
lead levels as low as 10 jig/dl (0.48 pimol/l),
previously considered to be safe, may also be
associated with renal functional abnormali-
ties. In a recent study, Staessen et al. (51)
determined renal function and indices of
lead exposure in a random population sam-
ple from Belgium, including 965 men and
1,016 women. The creatinine clearance was
inversely correlatedwith blood lead and zinc
protoporphyrin concentrations in both men
and women (Fig. 2). There was also a posi-
tive correlation between serum P2-
microglobulin and blood lead levels in men.
The same authors had previouslyfound only
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Figure 2. Relationship between measured creatinine and blood lead and zinc protoporphyrin levels,
adjusted for age, body mass index, and diuretic use. Regression lines and 95% confidence intervals (Cl)
are shown separately for men (n = 965) and women (n = 1,016). Reproduced from Staessen et al. (51) with
permission from the NewEnglandJoumal ofMedicine.
a weak positive correlation between serum
creatinine and blood lead concentrations in
a study conducted in London civil servants
(52). More recently, Kim et al. (53) reported
the results of a longitudinal study of 459
men followed for 35 years, as part of a study
of aging. They found a positive correlation
between blood lead levels and serum creati-
nine concentrations. A 10-fold increase in
blood lead level predicted an increase of 7
pmol/l (0.08 mg/dl) in serum creatinine
concentration. Whether such small changes
in renal function will result in clinically sig-
nificant health problems is uncertain and
will require even longer studies.
Lead nephropathy due to occupational
lead exposure. A multitude of studies have
documented an association between chronic
occupational lead exposure and impairment
of renal function (22,23,48,49,54).
Additionally, there appears to be an excess
risk of mortality from renal disease with
increasing duration of lead exposure
(55-58). Wedeen et al. (14) studied eight
subjects with occupational lead exposure of
3-6 years duration and found renal func-
tional abnormalities in four individuals.
Renal function improved with chelation
therapy in one subject reported to have pre-
clinical renal failure. The authors found no
changes in the tubular reabsorption ofphos-
phate or of sodium in their patients, but
noted proximal tubular abnormalities on
renal biopsy in three patients who had
decreased GFR. Baker et al. (48) evaluated
160 lead workers in two smelters and a
chemical plant. Increased blood urea nitro-
gen (BUN; >20 mg/dl, 7.14 mmol/l) was
found in 28. Eight workers had reduced cre-
atinine clearance. Lilis et al. (50) studied
449 lead workers with different levels oflead
exposure [from <40 to >100 pg/dl (<1.93 to
>4.83 pmol/l)], and found highly significant
correlations between BUN and creatinine
and zinc protoporphyrin levels. Hong et al.
(54) investigated the tubular and glomerular
function of six adults with occupational
exposure to lead. Lead exposure had ranged
from 3 months to 22 years, and all subjects
had elevated blood lead levels [>30 pg/dl
(>1.45 pmol/l)]. Serum creatinine and BUN
were normal in all subjects. Urinary excre-
tion of I2 microglobulin was also found to
be normal in all. However, glucose reabsorp-
tive capacity (TmG) was decreased in all
subjects. The presence ofglycosuria without
increased excretion oflow molecular weight
proteins suggests a selective effect oflead on
the proximal tubular glucose transporter
protein.
Several studies have used a control
group to assess the effect of lead exposure
on renal function. Two studies involving
heavily exposed individuals have shown a
positive association between lead and renal
impairment: Pinto de Almeida et al. (49)
compared the renal function of 52 primary
lead smelter workers [mean PbB 64.1 pg/dl
(3.1 pmol/l) with those of44 control work-
ers [mean PbB 25.5 pg/dl (1.23 pmol/l)].
Seventeen lead workers had a serum creati-
nine .1.5 mg/dl (132.6 pmol/l), compared
to only one control individual. Verschoor et
al. (59) compared the renal function of 155
lead workers to those of 126 control work-
ers. The mean blood lead level in exposed
workers was 2.29 pmol/l (47.4 pg/dl).
Several parameters ofrenal tubular function
were evaluated and found to be affected by
lead. Serum P2-microglobulin decreased
and urinary excretion of retinol binding
protein increased with increasing blood lead
level. Urinary excretion of NAG increased
with increasing blood lead and zinc proto-
porphyrin concentrations. The increased
urinary NAG appeared to be the most con-
sistent change.
A somewhat less clear relationship
between lead and renal dysfunction has been
found in individuals with less severe occupa-
tional exposure: Gerhardsson et al. (60)
studied 70 active and 30 retired lead smelter
workers and compared their renal function
to that of 41 workers who had not been
exposed to lead. The median lead level for
lead-exposed workers was 1.54 pmol/l (32
jig/dl). No clinical signs ofrenal impairment
were found, including no relationship
between urinary NAG and blood lead con-
centrations. Greenberg et al. (61) studied 38
industrial workers exposed to lead and cad-
mium for 11-37 years and found normal
creatinine clearances in all, despite a docu-
mented increase in lead burden in 36-58%
of the subjects. The lower blood lead con-
centrations of these workers, compared to
those studied by Pinto deAlmeida et al. (49)
or by Verschoor et al. (59), may explain
some ofthe negative findings.
Chia et al. (62) studied renal functional
parameters in 137 lead-exposedworkers [PbB
<60 pg/dl (<2.89 pmol/l)] and in 153 control
postal workers. The mean creatinine clear-
ances were not different between the two
groups. Only 8 subjects with lead exposure
had decreased creatinine dearance. SerumP2-
microglobulin was lower in lead-exposed sub-
jects, particularly in those over 30 years of
age. Buchet et al. (63) conducted a study of
lead-exposedworkers employed for a mean of
13.2 years and having a moderate exposure to
lead resulting in blood lead levels <62 pg/dl
(<2.99 pmol/l). They were unable to show
anyeffectoflead on renal function. Similarly,
Omae et al. (64) performed a cross-sectional
study of 165 lead-exposed men with a mean
blood lead level of 36.5 pg/cU (1.76 p-mol/l)
and found no change in serum creatinine or
in the urinary clearance of 32 microglobulin
or uric acid. These three studies appear to
confirm the previously reported observation
that renal failure is seldom observed when
blood lead levels remain below a critical
threshold of60 pg/dl (2.89 pmol/l).
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In summary, the preponderance ofstud-
ies suggests that occupational exposure to
lead results in renal functional abnormali-
ties, ranging from proximal tubular dysfunc-
tion to chronic renal failure and hyperten-
sion. Three studies show no change in renal
functional parameters and one shows abnor-
mal urinary concentrating ability (Table 1).
In general, longer exposure and higher
blood lead levels appear to be common fea-
tures among individuals who develop lead
nephropathy.
Does childhood leadpoisoning result in
lead nephropathy? Chronic nephropathy in
young adults following untreated lead poi-
soning in childhood was first described in
1929 from Queensland, Australia, by Nye
(10). The mode of exposure to lead was
somewhat unique among these children.
While playing on the verandas of wooden
houses typical of this region, the children
had ingested leaded paint debris and licked
the sweet-tasting lead-containing rain water
collected on the railings. In 1954,
Henderson (11) studied 401 individuals
who had been diagnosed as having lead poi-
soning between 1915 and 1935. Of these,
165 had died, 108 from nephritis or hyper-
tension, an incidence which far exceeded
that in the rest ofAustralia. The characteris-
tic clinical presentation included granular
contracted kidneys, hypertension, renal fail-
ure, and, in halfofthe cases, hyperuricemia
and gout (44,65,66). In additional articles,
Henderson and Inglis (67) showed that the
lead content ofbone in subjects between 20
and 49 years of age who were born in
Queensland and died ofgranular contracted
kidneys were significantly higher than in
subjects without such renal disease. In 1963,
Emmerson (68) showed that lead excretion,
following EDTA infusion, was consistently
elevated in patients with chronic renal dis-
ease and a history ofchildhood lead poison-
ing, but not in those with renal disease due
to other causes. Such observations appear to
be confined to Queensland and have not
been reported from other parts oftheworld.
Tepper (69) reported a follow-up study
of individuals from Boston, Massachusetts,
20-35 years after childhood lead poisoning.
Of 165 original cases, 139 were traced and
42 were screened with renal function tests.
Only 6 were found to have mild renal dys-
function. Similarly, in a study involving 62
adolescents from Baltimore, Maryland,
11-16 years after childhood lead poisoning,
Chisolm (70) found no evidence ofexcessive
mobilizable lead and no evidence of
nephropathy. Moel and Sachs (71) studied
62 subjects with severe childhood lead poi-
soning [PbB >100 pg/dl (>4.83 jimol/l)]
along with 19 age-matched control siblings
[PbB <40 pg/dl (<1.93 pmol/l)] from
Chicago, Illinois, 17-23 years after the chil-
dren had undergone chelation therapy.
They found no difference between the study
subjects and controls in any ofthe parame-
ters studied, induding serum creatinine, uri-
nary excretion ofP2 microglobulin, and sys-
tolic or diastolic blood pressure. This led the
authors to conclude thatlead nephropathy is
not a common sequela of childhood lead
poisoning in the United States. In none of
the above studies, however, did the investi-
gators use recently available and more sensi-
tive tests oftubular function such as urinary
excretion ofNAG or brush border enzymes.
Therefore, subtle changes in renal tubular
function may have been missed. Chisolm
(70) has suggested that the lead toxicity in
the Queensland population was of a differ-
ent type and had a more protracted course
than that observed in the United States.
A more recent retrospective study was
conducted in Boston, which compared the
renal function of individuals 50 years after
childhood lead poisoning with those of
carefully matched controls (72). The
authors found no evidence of impaired
renal function, as assessed by measurement
of glomerular filtration rate. In fact, the
mean creatinine clearance ofsubjects with a
past history of plumbism was higher than
that of controls. The authors, however,
noted a higher incidence of hypertension
among subjects with past lead poisoning
compared with controls (72).
Several recent studies suggest a relation-
ship between childhood lead exposure and
subsequent impairment of renal function.
In a cross-sectional study of lead and kid-
ney function in 744 men from Boston
[mean PbB 8.1 ± 3.9 pig/dl, (0.39 ± 0.19
pmol/l)], Payton et al. (73) found a signifi-
cant negative correlation between creati-
nine clearance and blood lead levels.
Bernard et al. (19) studied the renal tubular
function of 144 children, 12-15 years of
age, recruited from two schools in the
vicinity ofa lead smelter and 51 children of
similar age from a school in a rural area.
Children from the polluted areas had high-
er urinary excretion ofretinol binding pro-
tein, which paralleled the levels of lead in
blood and in the dust gathered from the
children's schools. Serum creatinine levels,
however, were not different between
groups. Verberk et al. (74) evaluated 151
children residing at various distances from
a lead smelter. They found a relationship
between blood lead concentration and the
activity of NAG in urine, suggesting renal
tubular damage due to lead (Fig. 3). They
failed, however, to find changes in retinol
binding protein. In a recent epidemiologic
study of454 individuals with a diagnosis of
childhood lead poisoning between 1923
and 1966, there was an increased mortality
from cardiovascular disease and cerebrovas-
cular disease compared to the general pop-
ulation, especially among women (75).
Chronic nephritis, however, was not a sig-
nificant cause ofdeath in this population.
Although a common occurrence in acute
lead poisoning, renal tubular transport
abnormalities have rarely been reported in
patients with chronic lead nephropathy,
whether from Queensland or in patients
with occupational lead exposure. Hong et al.
(54) reported a reduction in renal tubular
glucose reabsorption in lead workers with
otherwise normal renal function, as assessed
by serum creatinine concentrations. Buchet
et al. (63) studied 25 lead-exposed workers
with blood lead levels below 62 pg/dl (2.99
pmol/l). There were significant positive cor-
relations between urinary lead excretion and
urinary amino acids (r= 0.595) and urinary
lactate dehydrogenase (r = 0.407) excretion.
There were no changes in serum creatinine
or in creatinine clearance in thesesubjects.
In a retrospective study of 134 children
and adolescents 8-13 years after treatment
for severe lead poisoning, we found subtle
changes in renal tubular function (M.
Loghman-Adham, unpublished data). At the
time ofthe study, the mean blood lead level
was 18.5 jig/dl (0.89 pmol/l). Creatinine
clearance was normal (>80 ml/min/1.73 M2)
in all but three children. Thirty-two children
(24%) continued to have glycosuria (>124.8
mg/24 hr) and 94 (70%) had persistent
aminoaciduria(UJ=/Cr > 0.23).
In summary, sustained environmental
lead exposure, particularly during child-
hood, can under certain circumstances result
in chronic lead nephropathy. Three studies
from the United States have failed to show
any evidence of nephropathy in individuals
who had been treated for childhood lead
poisoning. One study, while confirming the
absence ofchronic nephropathy, shows per-
sistent tubular dysfunction, manifested by
glycosuria and aminoaciduria. Among four
large epidemiologic studies ofchildren with
increased lead exposure, three studies found
evidence of renal tubular dysfunction.
None, however, found any evidence of
nephritis or reduced glomerular filtration.
Lead nephropathy in "moonshine"
drinkers. A high incidence of chronic lead
nephropathy has been described in "moon-
shine" drinkers, those who drink illegally dis-
tilled whiskey. Typically these individuals
have also been reported to suffer from hyper-
tension and hyperuricemia with gout
(13,14,53,76,77). This illegal whiskey has
commonly been distilled in rural areas in the
Southeastern United States. The alcohol is
often brewed in galvanized tubs and distilled
in truck radiators. Lead battery plates, moth
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balls, or drain deaner are sometimes added to
the mash to accelerate fermentation or to add
flavor (13). Morgan et al. (13) studied 11
patients, betwveen 34 and 50 years ofage, who
had lead poisoning and a history ofpast or
present consumption of illicit alcohol. Two
additional patients with a history ofoccupa-
tional lead exposure were also induded. All
had confirmatory evidence of excessive lead
accumulation, as determined by the EDTA
lead mobilization test. However, blood lead
levels were not given, thus making it difficult
to assess recent lead exposure. Renal finction
was impaired in all but one patient with an
average serum creatinine of 2 ± 0.7 mg/dl
(range 1.2-3.8 mg/dI) [176.8 ± 62 pmol/l,
(range 106-336 pmol/l)]. Six of 13 patients
had proven gout. Renal biopsy showed inter-
stitial fibrosis, obsolescent glomeruli, arterial
and arteriolar changes, and the presence of
eosinophllic indusion bodies in many tubular
cells. These patients appear to represent cases
with severe acute and chronic lead poisoning
and significant kidney damage. Other toxic
substances present in the brews may have
contributed to theiroverall toxicity.
Other Symptoms of Chronic
Lead Toxicity
Leadin hypenericemia andgout. The associ-
ation between lead poisoning and hyper-
uricemia and gout was described as early as
1703 (78). In 1859, Garrod observed the
relationship between the ingestion of forti-
fied ports, later shown to be heavily contami-
nated with lead, and the development of
gouty arthritis (79,80). With the popularity
of leaded port wine, gout was a common
occurrence among English aristocracy during
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the nineteenth century (78). Emmerson (6$)
investigated a group of patients with renal
insufficiency in whom the nature of renal
disease was not readily apparent. Evidence of
excessive past lead absorption was demon-
strated in 16 patients with the use of the
EDTA lead mobilization test. Gout was
found in half of the patients with chronic
lead nephropathy but was infrequent in
patients with chronic nephropathy due to
other causes. About halfofthe patients with
saturnine or lead-induced gout were female,
a much higher frequency of females than
that observed for gout in general. Campbell
et al. (20) studied 283 individuals from
Scotland, who lived for an average of 21.5
years in houses with water lead levels in
excess of100 pgl (0.48 pmol/l). Fifteen sub-
jects had increased serum urea and 20 sub-
jects hadhyperuricemia.
In the Southeastern United States, con-
sumption of "moonshine" whiskey, known
to be adulterated with lead, has been associ-
ated with a high incidence ofhypertension,
hyperuricemia, and gout (13,81,82).
Although hyperuricemia is seen in chronic
renal failure, the incidence of gout is much
higher in chronic lead nephropathy than in
other types of renal failure (28,83,84). In
patients with lead nephropathy, there is no
evidence of overproduction of uric acid,
suggesting that lead may impair the renal
tubular secretion of uric acid (65,82,85).
To determine the relationship between lead
and gout nephropathy, Batuman et al. (86)
examined the body lead burden of 44 men
with gout, without previous symptoms of
lead poisoning, using the EDTA lead mobi-
lization test. Among them, halfhad chronic
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Figure 3. Relationship between blood lead levels and urinary excretion of N-acetyl
(NAG) adjusted to age 5 years in 151 children of 3-6 years of age residing in th
smelter. Values of NAG/g creatinine are plotted on a log scale. Reproduced from V
permission from The Helen Dwight Reid Educational Foundation and Archives ofEnv
renal disease. The amount of mobilizable
lead was significantly greater in patients
with gout who had renal impairment than
in patients who had normal renal function.
Craswell et al. (87) studied 44 Australian
patients with chronic renal failure.
Nineteen of23 patients with gout and 8 of
19 patients without gout had positive
EDTA lead mobilization tests. The authors
concluded that gout, in the presence of
chronic renal failure, is a useful marker of
chronic lead poisoning. Long-term follow-
up studies have indicated that neither hype-
ruricemia nor gout can lead to renal failure
in the absence ofother renal disease (88).
Leadandhypertension. There is consid-
erable evidence that excessive lead absorp-
tion predisposes individuals to hypertension
even in the absence of renal insufficiency
(89-92). Verschoor et al. (59) compared the
renal function of 155 lead workers [mean
blood lead level 2.29 pmol/l (47.7 pg/dl)] to
those of 126 control workers. Both systolic
and diastolic blood pressures were higher in
the lead-exposed group, with a significant
correlation between blood lead levels and
systolic blood pressure. De Kort et al. (93)
compared the blood pressures of53 workers
exposed to lead and cadmium with blood
pressures obtained in 52 nonexposed work-
ers. The mean blood lead levels were 47.4
jg/dl (2.27 pmol/l) and 8.1 pg/dl (0.39
pmol/l) for the two groups, respectively. A
positive correlation was found between
blood lead levels and systolic blood pressure.
The authors failed, however, to show any
difference in kidney fur
two groups, suggesting t
of hypertension may be
of lead nephropathy. do,
studied 166 lead worke
subjects and found a hiE
blood pressure among
group but no difference i
pressures between the twi
Exposure to lower
lead, such as via environ
also been linked to hype
al. (95) evaluated the re
lead and blood pressure l
during the second Nat
Nutrition Examination '
II). They found a di
between blood lead lev
diastolic blood pressure
subject's sex or race. Th
present at blood lead lev
Weiss et al. (96) studied
lead with blood pressuri
study over 5 years in a co
policemen. They conc
blood lead level was a I
quent elevation of systo
Wolf et al. (97) studie
male law enforcement
occupational exposure t
blood lead level of the si
pg/dl (0.38 ± 0.17 pmol,
nificant effect of lead
blood pressure. In a rc
study of childhood plun
(98) among matched pai
of controls were on antihypertensive med-
ications compared with 41% ofindividuals
w'_ZELiFio with childhood lead poisoning. Schwartz
M* gB(99) has performed a meta-analysis based
on 15 published papers on the effect of
blood lead on systolic blood pressure in
males. He evaluated the estimated change
in blood pressure associated with a change
in blood lead from 10 to 5 pg/dl in each
study. From this careful analysis he con-
cluded that there is a causal association
between lead and blood pressure.
Animal studies have confirmed the
observations made in human populations.
Exposure of rats to lead during develop-
ment can result in progressive renal insuffi-
ciency and hypertension later in life (41).
Additionally, low-level lead exposure in rats
causes a progressive elevation of systolic
blood pressure without evidence of renal
1,000 1,200 impairment (100,101). Dietary calcium can influence the effects of lead on blood
pressure: lower dietary calcium intake is
P-D-glucosaminidase associated with higher blood pressure and
e proximity of a lead decreased calcium intake can aggravate the
/erberk et al. (74) with toxic effects oflead exposure (95,102).
ironmentalHealth. The pathogenic mechanisms for lead-
induced hypertension remain unclear.
iction between the Vascular changes have been shown to occur
-hat the mechanism in acute lead poisoning associated with
different from that nephropathy (103). Lead causes increased
s Santos et al. (94) responsiveness to cx adrenergic stimulation
.rs and 60 control (104-106), an augmented and prolonged
gher mean diastolic pressor response to norepinephrine stimula-
the lead-exposed tion, and reduced effectiveness of isopro-
in the systolic blood terenol in lowering blood pressure (10/).
o groups. These findings suggest an interaction of
concentrations of lead with calcium signaling mechanisms
mental sources, has involved in smooth muscle contraction
rtension. Harlan et (Fig. 1) (99,108). Hypertension may also be
lationship between the result of lead-induced changes in the
using data obtained vasculature, the renin-angiotensin system
tional Health and (109-111), or in renal ion transport
Survey (NHANES- processes (28). Lead has been shown to
rect relationship increase the in vitro sodium-lithium coun-
els and systolic or tertransport in red blood cells obtained
, regardless of the from healthy normotensive individuals
iis relationship was (112). The changes are similar to those
rels below 30 pg/dl. observed in red blood cells from patients
the relationship of with essential hypertension. Cardenas et al.
e in a longitudinal (113) studied more than 20 tests of renal
:ohort of89 Boston function in 50 lead workers. The most
luded that a high striking effect oflead was interference with
predictor of subse- renal synthesis of eicosanoids, resulting in
lic blood pressure. lower excretion of 6-keto-PGF ,. The
d a group of 507 authors speculated that the depletion of
t officers without prostaglandins may enhance sodium reten-
to lead. The mean tion and the pressor response to angiotensin
ubjects was 8 ± 3.5 II and vasopressin, changes that mimic
/1). There was a sig- those seen in essential hypertension.
only on diastolic In summary, excessive lead absorption
ecent longitudinal results in hypertension, both in humans
nbism from Boston and in experimental animals, even in the
irs ofsubjects, 14% absence of nephropathy. Epidemiologic
Volume 105, Number9, September 1997 * Environmental Health Perspectives
50
20
10
-a
0)
CD
z
5
0 200
934Reviews * Chronic lead nephropathy
studies have shown a clear association
between blood lead levels and blood pres-
sure. The mechanisms of lead-induced
hypertension include a direct effect oflead
on the vasculature, increased responsiveness
to cx adrenergic stimulation, interference
with the renin-angiotensin system, an
effect on the calcium signaling mechanism
involved in smooth muscle contraction,
and interference with renal synthesis of
vasodilatory prostaglandins and with ion
transport mechanisms.
Methods to Assess Increased
Body Lead Burden
Lead stored in bone has a biologic halflife of
approximately 30 years. Over 90-95%
(70-80% in children) of body lead burden
is retained in bone where it is available for
exchange with blood (114). Blood lead lev-
els provide a poor estimate of past lead
absorption because the levels can vary with
recent ingestion (8,83,115). Cumulative
lead absorption, or body lead burden, is best
evaluated by the use of the CaNa2EDTA
lead mobilization test (44,68). The test con-
sists of intramuscular administration of one
or two doses of 1 g EDTA every 12 hr in an
adult or of50 mg/kg in a child, followed by
collection of urine for 8 to 24 hr (116). In
patients with reduced renal function, there
is a delay in the excretion of lead chelate
(117) and the collection time is extended to
72 hr. An amount of lead mobilized in
excess of600 mg (or >1 pg Pb/mg EDTA in
a child) is considered proofofincreased lead
burden (115). Unfortunately, the EDTA
challenge test is not a consistent predictor of
body lead burden (118). Furthermore, the
test is fraught with technical difficulties and
has a potential to increase lead toxicity.
Therefore, the EDTA mobilization test will
probably be abandoned in the future and
replaced by noninvasive tests, such as in vivo
X-ray fluorescence (XRF), which have now
become available (119). A drug that could
be used as a possible substitute for EDTA is
the water soluble and orally active chelating
agent dimercaptosuccinic acid (DMSA or
succimer). Limited experience suggests that
DMSA does not result in increased risk of
lead toxicity such as encephalopathy.
Although widely used in the former Soviet
Union for the treatment ofheavy metal poi-
soning, experience with DMSA has been
limited in the United States (120,121).
A more recent and much less invasive
test for evaluation of lead burden involves
the quantitation of bone lead with in vivo
XRF (122-132). Measurements taken at
the midtibial diaphysis using a K-XRF
instrument appear to be very reliable (125).
The lead fluorescent signal is normalized to
the coherent scatter signal, which results
principally from calcium in bone mineral
(125). Using older equipment, the mini-
mum detection limit ofXRF was 25 pg/g
(123). However, this limit has continued to
decrease with improvements in technology,
with a current sensitivity in the range of 5
pg/g). At present, XRF is not widely avail-
able for routine clinical use; however, since
it is an accurate and noninvasive means of
determining body lead burden, its use will
undoubtedly become morewidespread.
Tests for Detection of Kidney
Damage Due to Lead
Chronic lead nephropathy can be missed in
its early stages because changes induced by
chronic low-level lead exposure are subtle
and not reflected by changes in routine renal
function tests such as BUN and serum creati-
nine concentrations. More than 50% ofkid-
ney function may be lost before significant
changes in serum creatinine are detected..
Recent studies have focused on the use of
more sensitive tests to detect lead-induced
renal dysfunction in its early stages, when
such changes might still be reversible by
treatment and abatement of lead sources.
Currendy recommended tests ofnephrotoxi-
city include the measurement of urinary
excretion of proteins, which, according to
their size, reflect the functional integrity of
the proximal tubule (retinol binding protein
or 2 microglobulin) or of the glomerulus
(albumin, immunoglobulin G) (133).
Although I2 microglobulin can be degraded
in acid urine, retinol binding protein is not
hydrolyzed in acidic pH and therefore may
be a more reliable marker. Expressing the
urinary excretion of low molecular weight
proteins as fractional clearance (ratio of
clearance of protein over creatinine clear-
ance) has been used to increase the sensitivi-
ty of such tests (134). More sensitive tests,
such as determination of levels of enzymes
excreted in the urine, have revealed evidence
of tubular toxicity in patients with chronic
low-level lead exposure, whether secondary
to environmental or occupational lead
sources. The most sensitive test appears to
be urinary excretion ofNAG (74,135-140).
Verschoor et al. (59), in a study of lead
workers with blood lead levels below 60
pg/dl (2.89 pmol/l), found the excretion of
NAG to be the most sensitive marker of
renal tubular dysfunction. There was, how-
ever, only a modest increase in urinary NAG
excretion (from 3.0 to 3.7 U/mg creatinine)
in workers with the highest blood lead con-
centrations (>3 pmol/l) compared to those
with low (<1 pmol/l) bloodlead.
It has been suggested that NAG might
be an overly sensitive test because its levels
are increased in animals with continuous
low-level lead exposure at a time when no
other signs ofkidney damage are detectable
(42,69). More recently, the heat-stable
isoenzyme ofNAG has been used as a mark-
er of lysosomal breakdown in proximal
tubular cells (138). Endo et al. (136) studied
46 lead refinery workers with long-term
exposure to lead dust; they found markedly
increased urinary NAG activity in workers
whose blood lead levels exceeded 80 pg/dl
(3.86 pmol/l). In one study in rats, ligandin
appeared to be a better indicator of tubular
injury because it correlated with changes in
tubular morphology (42). No information is
available on ligandin excretion in humans.
Bernard et al. (19) studied children
recruited from two schools in the vicinity of
a lead smelter, with children from a rural
area used as controls. Urinary excretion of
retinol binding protein was elevated in chil-
dren from the polluted areas and correlated
with blood lead levels. Urinary P2
microglobulin and urinary NAG were ele-
vated only in children from one ofthe pol-
luted areas, despite similar blood lead levels
between children from these areas.
Cardenas et al. (113) used a battery ofmore
than 20 potential indicators of renal func-
tion in 50 workers exposed to lead and in
50 control subjects. The most striking effect
oflead was interference with renal synthesis
of eicosanoids, resulting in lower excretion
of 6-keto-PGFl. Increased urinary NAG
activity was also found in lead-exposed
workers. The authors found no correlation
between urinary NAG and blood lead or
zinc protoporphyrin levels or the duration
of lead exposure. There was, however, a
positive correlation between urinary NAG
and urinary cadmium excretion.
Fels et al. (141) studied various markers
of renal proximal tubule injury in 81 male
lead-exposed workers and 45 age-matched
controls. The mean blood lead level oflead-
exposed subjects was 2.03 pmol/l (42 pg/dl),
with a mean duration ofexposure of7 years.
Urinary6-keto-PGFI, levels were higher in
lead-exposed workers, as were urinary
thromboxane B2, urinaryPGF2., and PGF2
excretion. These findings appear to be oppo-
site those reported above by Cardenas et al.
(113). Intestinal alkaline phosphatase and
brush border antigen (BBA) excretion were
also increased in 27% and 16% ofsubjects,
respectively. In a subsequent study of the
same subjects, Pergande et al. (142) mea-
sured the urinary excretion oflow molecular
weight proteins and tubular enzymes as
indicators ofproximal tubular damage; they
found the combination ofurinary NAG and
acl microglobulin to be useful in the early
detection oflead-induced tubularchanges.
Chia et al. (143) correlated urinary al
microglobulin and P2 microglobulin in 128
lead-exposed workers with time-integrated
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blood lead indices derived from serial blood
lead determinations over time. There was a
correlation between urinary (x microglobu-
lin and time-integrated blood lead, but not
with recent blood lead levels. dos Santos et
al. (94) measured biochemical markers of
kidney damage in 166 lead-exposed workers
and in 60 controls. The median blood lead
levels were 36.8 pg/dl (1.78 pmol/l) in
exposed workers and 11.6 pg/dl (0.56
pmol/l) in controls. Urinary NAG washigh-
er in the lead-exposed group and correlated
with blood lead levels and with duration of
exposure. In contrast, urinary excretion of
two brush border enzymes, y-glutamyl-
transpeptidase and alanine-aminopeptidase,
were not increased in lead exposedworkers.
In summary, conventional renal function
tests are insensitive and cannot detect early
signs ofrenal dysfunction in persons exposed
to occupational or environmental lead.
Measurement ofurinary excretion ofa panel
of low molecular weight proteins and
enzymes provides the most sensitive means to
evaluate renal tubular dysfunction after lead
exposure. These tests are, however, nonspe-
cific and can be abnormal in persons exposed
to cadmium or to other nephrotoxins.
Therefore, abnormal values must be correlat-
edwith evidence ofchroniclead exposure.
Summary and Conclusions
Despite significant reductions in industrial
and environmental sources of lead, low-
level lead exposure remains a major health
problem in many countries. Children are
particularly susceptible because of their
exploratory activity and higher gastrointesti-
nal absorption. Acute lead poisoning in
humans and in animal models causes
destruction ofproximal tubular architecture
with functional disturbances, including
aminoaciduria, glycosuria, and phospha-
turia (Fig. 1). These changes are reversible
after chelation therapy. Recent observa-
tions, however, have revealed persistent
aminoaciduria and glycosuria up to 13 years
after treatment of lead poisoning. Chronic
lead poisoning, secondary to occupational
exposure or consumption of lead-contami-
nated illicit alcohol, may result in what has
been termed lead nephropathy. The latter
seems to develop when blood lead levels
exceed a threshold of 60 pg/dl (2.89
pmol/l). Renal histologic changes ofchron-
ic lead nephropathy are nonspecific and
include interstitial fibrosis, tubular atrophy,
and glomerular sclerosis. They lead to pro-
gressive and irreversible renal failure often
associated with hypertension, hyper-
uricemia, and gout. The development of
gout appears to be a common feature of
lead nephropathy and may be the result ofa
direct effect of lead on urate secretion.
Chronic nephropathy, subsequent to child-
hood lead poisoning, has been reported
from Queensland, Australia. However, stud-
ies from the United States have failed to
show any such sequelae in children up to 35
years after childhood lead poisoning. Recent
longitudinal studies, however, have shown
direct correlations between blood lead levels
and serum creatinine or blood lead and
blood pressure. Lead-induced hypertension
can occur in the absence of nephropathy.
The mechanisms include vascular changes,
increased sensitivity to catecholamines, and
an effect of lead on the renin-angiotensin
system and on calcium signaling mecha-
nisms, resulting in enhanced vasoconstric-
tion and hypertension (Fig. 1).
Because >90% oflead is stored in bone,
blood lead levels are a poor indicator of
total body lead burden. The EDTA lead
mobilization test has been used extensively
to document increased body lead burden,
but more recently, less invasive tests such as
measurements of bone lead by X-ray fluo-
rescence have gained in popularity. Early
renal tubular dysfunction, secondary to
low-level lead exposure, can be evaluated
with measurement of urinary excretion of
low molecular weight proteins (al and 1P2
microglobulins, retinol binding protein) or
of the lysosomal enzyme NAG, as well as
by a host ofother brush border proteins. It
remains uncertain whether the tubular dys-
function detected by these sensitive mark-
ers is ofany long-term clinical significance.
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